- GE HealthCare has teamed with Mayo Clinic to advance medical imaging, artificial intelligence and theranostics, a type of cancer treatment that involves imaging and targeted therapeutics.
- The organizations will collaborate on the application of AI to magnetic resonance imaging, the automation of diagnostic and interventional ultrasound and other activities that could improve patient care.
- GE HealthCare has formed a series of partnerships since separating from its parent company, striking deals with companies including Boston Scientific, Johnson & Johnson and Medtronic.
GE HealthCare and other parts of its former parent company, GE, have a long history of working with Rochester, Minnesota-based Mayo, teaming up with the hospital to test remote monitoring devices, found a gene therapy software startup and develop a medical electronic record system.
The latest deal brings together scientists, technology developers and clinicians working at GE HealthCare and Mayo to collaborate on four core areas that could improve the diagnosis and treatment of medical conditions.
GE HealthCare and Mayo will work to enhance MRI with AI-enabled exams, combine theranostic imaging and dosimetry to improve cancer care, and make diagnostic and interventional ultrasound easier to use and read. They will also work together to use data, AI and digital health platforms to personalize imaging.
“This collaboration brings our research and clinical teams’ expertise and feedback closer to product development and commercialization of innovation, ultimately accelerating the rate of translation of our research to patient care and offering greater opportunity for global impact,” Matthew Callstrom, chair of radiology at Mayo Clinic, said in a statement.
If the alliance accelerates the development of technologies and increases their impact, it could help GE HealthCare work through some of the challenges it faces. The company grew sales by 7% in the second quarter, but BTIG analysts have questioned its longer-term prospects, cautioning that its dominant position in mature end-markets could constrain its performance.